Vaccine liability rhetoric is back in the legislative record - the trade is the tail risk premium
The Opportunity
The investable mechanism is not a passed law today; it is the reintroduction of a liability-regime challenge that can widen perceived tail risk for vaccine-exposed manufacturers. 7A resolves a SHORT on the proxy instrument because the directional asymmetry in these episodes is usually negative: even low-probability liability shifts can raise discount rates for affected sub-sectors. The edge is recognising that the market often reprices probability-weighted legal risk before legislative outcomes are known.
The Timing
Mixed 55 tape with crosswind 60 means policy headlines can whipsaw quickly and then mean-revert when nothing advances. Freshness is 65/100 and the oldest claim date in the artefact is July 2025, so this is not brand new, but it is live enough to resurface. The key tripwires are concrete committee action, an official Senate companion bill page, or explicit industry positioning that signals the issue is moving from rhetoric to process.
The Evidence
The primary artefact cited upstream is the Congress tracker page for congress.gov . Upstream synthesis also references specialist commentary (for context) but the only hard, non-debatable evidence needed for this signal is that a bill exists with an introducer and referral path.